LATEST PRICE
$226.83
H 227.88 · L 225.86
Vol 670K · May 18
COMPOSITE SCORE
63.6
out of 100
RECOMMENDATION
WATCH
CONFIDENCE
71%
MODULES RUN
8/8
May 18, 14:16 UTC
Top Signals
- • CEO assessment: Strong leadership with significant experience and a solid track record in the healthcare sector.
- • Insider ownership: Moderate
- • Long CEO tenure with strategic acquisitions enhancing growth.
- • Consistent dividend payouts indicating strong capital allocation.
- • Recent governance improvements and transparency initiatives.
Price History
showing 7 of 30 days
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| May 18, 2026 | $226.71 | 227.88 | 225.86 | $226.83 | +0.12 (+0.1%) | 670K |
| May 15, 2026 | $230.77 | 232.14 | 226.44 | $226.71 | -4.09 (-1.8%) | 12.2M |
| May 14, 2026 | $231.00 | 231.76 | 229.16 | $230.80 | +0.38 (+0.2%) | 7.0M |
| May 13, 2026 | $225.82 | 230.80 | 225.44 | $230.42 | +6.16 (+2.7%) | 7.5M |
| May 12, 2026 | $223.00 | 227.65 | 221.65 | $224.26 | +2.83 (+1.3%) | 8.6M |
| May 11, 2026 | $221.32 | 223.28 | 220.37 | $221.43 | +0.11 (+0.0%) | 6.2M |
| May 08, 2026 | $222.94 | 223.37 | 220.92 | $221.32 | -1.19 (-0.5%) | 5.6M |
Module Breakdown — May 18, 14:16 UTC
| Module | Score | Confidence | Signals |
|---|---|---|---|
| Moat |
85.0 |
65% | • Switching costs: High | Network effects: Moderate • Brand strength: High | Market position: Dominant • Strong global brand recognition • Diverse product portfolio • High investment in R&D • Regulatory compliance challenges |
| Leadership |
85.0 |
65% | • CEO assessment: Strong leadership with significant experience and a solid track record in the healthcare sector. • Insider ownership: Moderate • Long CEO tenure with strategic acquisitions enhancing growth. • Consistent dividend payouts indicating strong capital allocation. • Recent governance improvements and transparency initiatives. • No major scandals impacting credibility in recent years. |
| Momentum |
78.0 |
95% | • Golden cross: MA50 (234.24) > MA200 (209.51) • RSI neutral: 48.3 • MACD bullish crossover: -1.1827 > signal -2.3470 • Positive 20-day momentum: +0.3% |
| FinancialHealth |
72.0 |
85% | • Profitable: Net income $5235M • Positive revenue growth QoQ: +0.3% • Positive free cash flow: $1465M • Very high leverage: Debt/EBITDA 6.4x |
| Sentiment |
70.0 |
15% | • Analysed 7 articles over 7 days (2 sentiment-scored) • Average sentiment: +0.50 — Positive: 2, Neutral: 0, Negative: 0 • Most bullish: "NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE C…" (score +0.50) |
| Institutional |
50.0 |
40% | • No insider transactions found in last 90 days (SEC EDGAR Form 4) |
| Macro |
50.0 |
15% | • Sector performance data unavailable |
| Valuation |
50.0 |
78% | • P/E ratio unavailable (negative earnings) |
Score History
showing 7 of 29 runs
| Date (UTC) | Score | Recommendation | Confidence | Modules |
|---|---|---|---|---|
| May 18, 14:16 | 63.6 | WATCH | 71% | 8 |
| May 17, 09:13 | 62.3 | WATCH | 72% | 8 |
| May 16, 12:23 | 62.3 | WATCH | 72% | 8 |
| May 15, 11:14 | 62.3 | WATCH | 72% | 8 |
| May 14, 10:08 | 62.3 | WATCH | 72% | 8 |
| May 13, 09:14 | 61.5 | WATCH | 72% | 8 |
| May 12, 09:42 | 61.7 | WATCH | 71% | 8 |